Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

The Value of Surgery for Brain Metastases
Author
Howard (Jack) West, MD

I briefly mentioned the potential value of surgery for a solitary brain metastasis, where it is commonly used, in another post. Today I'll talk more specifically about where the role for surgery has been specifically tested for brain metastases in lung cancer. Aside from possibly removing the only lesion (in certain cases, where it can be associated with long-term survival, as I described in my post on solitary brain metastases), neurosurgery is used to offer rapid relief of symptoms resulting from the mass effect of a large tumor, to improve local control of brain metastases, and/or to clarify the tissue diagnosis when there is some question about the underlying diagnosis of a brain lesion. Improvements in anesthesia and neurosurgery have made this intervention safer and more feasible for patients over time.

One way to assess the value of surgery in the treatment of brain metastases is by comparing the results of WBRT vs. a combination of neurosurgery and SRS, and three randomized trials have done that (abstracts here and here and here). The first was an influential trial by Patchell and colleagues (abstract here), of 48 patients with a single brain metastasis who underwent surgery followed within two weeks by WBRT (36 Gy over 12 fractions) or WBRT alone. This study, although small, did show very clear and statistically significant improvements in likelihood of recurrence of brain metastases (20% vs. 52%) and median overal survival (40 vs. 15 wks). These results were corroborated by another trial (abstract here) of 63 patients with a single brain lesion who received WBRT alone or preceded by surgery, showing a significant improvement in survival (10 vs. 6 months). These trials both also showed that patients undergoing a combination of surgery and WBRT remained functionally independent for longer. The third and largest trial (abstract here), with 84 patients who also had a single brain lesion, actually did not demonstrate a significant improvement in survival or functional status, but this trial had patients with a greater burden of distant disease than the other trials. The results of these three studies are shown here:

Surgery WBRT solitary brain met table (click to enlarge)

The differences among these trials reminds us that the value of surgery for brain metastases is still questionable, and it is a most compelling consideration for patients with a single metastasis, good performance status, and controlled disease outside of the brain. There is really remarkably little experience to guide us on the value of surgery for more than a solitary brain metastasis, but it is generally felt to be far less appealing than in the more commonly advocated setting of treating a single brain metastasis.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on